Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome

Contributed by: PR Newswire

Tags

H.-Lundbeck-A/S

More Like This

Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)

Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting

Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting

Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy

Lundbeck's bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies

Lundbeck to highlight mechanistic insights on bexicaserin's dual mode of action at the European Epilepsy Congress

Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting

Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting